Hamps Bio Limited, a Gujarat-based pharmaceutical and FMCG company, has emerged as a promising player following its recent IPO. The company’s focus on pharmaceutical formulations and freeze-dried products positions it uniquely in the market. This blog analyzes the Hamps Bio share price target for 2025 to 2040, along with details about its IPO, business, financials, and peer comparison.
Hamps Bio IPO Details
| Details | Information |
|---|---|
| Issue Size | ₹6.22 crore |
| Price Band | ₹51 per share |
| Lot Size | 2,000 shares |
| Minimum Investment | ₹102,000 |
| Subscription Period | Dec 13 – Dec 17, 2024 |
| Listing Date | Dec 20, 2024 |
| Oversubscription Rate | 1,057 times |
Hamps Bio Company Details
| Founded | 2007 |
|---|---|
| Headquarters | Gujarat, India |
| Segments | Pharmaceutical Formulations, Freeze-Dried Products |
The company markets over 180 pharmaceutical products under the “Hamps” brand, including tablets, syrups, and injectables, while the “FzyEzy” brand focuses on freeze-dried fruits and vegetables.
Hamps Bio Business Overview
| Segment | Details |
|---|---|
| Pharmaceuticals | Ethical marketing of products for therapeutic areas |
| Freeze-Dried Products | Advanced freeze-drying technology for quality preservation |
| Export Reach | Products exported to six countries, including the U.S. |
The company has a strong distribution network, reaching 8,000 doctors and medical stores across India monthly.
Hamps Bio Financials
| Metric | FY22 (₹ Lakh) | FY23 (₹ Lakh) | FY24 (₹ Lakh) |
|---|---|---|---|
| Revenue from Operations | 534.05 | 557.81 | 647.53 |
| Profit After Tax | 12.15 | 35.90 | 50.07 |
| Net Worth | 100.57 | 136.30 | 337.42 |
| EPS (₹) | 0.51 | 1.50 | 1.76 |
The company’s revenue has shown consistent growth, reflecting a strong market presence and operational efficiency.
Hamps Bio Shareholding Pattern
| Category | Pre-IPO (%) | Post-IPO (%) |
|---|---|---|
| Promoters | 100 | 71.99 |
| Public Investors | 0 | 28.01 |
Promoters retain a majority stake, ensuring stability while offering opportunities for public investment.
Hamps Bio Share Price Target 2025 To 2040
Hamps Bio Share Price Target for each year from 2025 to 2040 is provided below with month-wise projections.
Hamps Bio Share Price Target 2025
| Month | Bullish Price (₹) | Bearish Price (₹) |
|---|---|---|
| January | 60 | 55 |
| February | 62 | 56 |
| March | 64 | 58 |
| April | 66 | 60 |
| May | 68 | 62 |
| June | 70 | 64 |
| July | 72 | 66 |
| August | 74 | 68 |
| September | 76 | 70 |
| October | 78 | 72 |
| November | 80 | 74 |
| December | 85 | 75 |
Hamps Bio Share Price Target for 2025 indicates steady growth between ₹55 and ₹85.
Hamps Bio Share Price Target 2026
| Month | Bullish Price (₹) | Bearish Price (₹) |
|---|---|---|
| January | 90 | 80 |
| February | 92 | 82 |
| March | 95 | 85 |
| April | 98 | 88 |
| May | 100 | 90 |
| June | 105 | 95 |
| July | 110 | 100 |
| August | 115 | 105 |
| September | 120 | 110 |
| October | 125 | 115 |
| November | 130 | 120 |
| December | 135 | 125 |
Hamps Bio Share Price Target for 2026 reaches a potential high of ₹135.
Hamps Bio Share Price Target 2027
| Month | Bullish Price (₹) | Bearish Price (₹) |
|---|---|---|
| January | 140 | 130 |
| February | 145 | 135 |
| March | 150 | 140 |
| April | 155 | 145 |
| May | 160 | 150 |
| June | 165 | 155 |
| July | 170 | 160 |
| August | 175 | 165 |
| September | 180 | 170 |
| October | 185 | 175 |
| November | 190 | 180 |
| December | 195 | 185 |
Hamps Bio Share Price Target for 2027 predicts a range of ₹130 to ₹195.
Hamps Bio Share Price Target 2028
| Month | Bullish Price (₹) | Bearish Price (₹) |
|---|---|---|
| January | 200 | 190 |
| February | 210 | 200 |
| March | 220 | 210 |
| April | 230 | 220 |
| May | 240 | 230 |
| June | 250 | 240 |
| July | 260 | 250 |
| August | 270 | 260 |
| September | 280 | 270 |
| October | 290 | 280 |
| November | 300 | 290 |
| December | 310 | 300 |
Hamps Bio Share Price Target 2029
| Month | Bullish Price (₹) | Bearish Price (₹) |
|---|---|---|
| January | 320 | 310 |
| February | 330 | 320 |
| March | 340 | 330 |
| April | 350 | 340 |
| May | 360 | 350 |
| June | 370 | 360 |
| July | 380 | 370 |
| August | 390 | 380 |
| September | 400 | 390 |
| October | 410 | 400 |
| November | 420 | 410 |
| December | 430 | 420 |
Hamps Bio Share Price Target 2030
| Month | Bullish Price (₹) | Bearish Price (₹) |
|---|---|---|
| January | 450 | 430 |
| February | 460 | 440 |
| March | 470 | 450 |
| April | 480 | 460 |
| May | 490 | 470 |
| June | 500 | 480 |
| July | 510 | 490 |
| August | 520 | 500 |
| September | 530 | 510 |
| October | 540 | 520 |
| November | 550 | 530 |
| December | 560 | 540 |
Hamps Bio Share Price Target 2040
| Month | Bullish Price (₹) | Bearish Price (₹) |
|---|---|---|
| January | 1,000 | 900 |
| February | 1,020 | 920 |
| March | 1,040 | 940 |
| April | 1,060 | 960 |
| May | 1,080 | 980 |
| June | 1,100 | 1,000 |
| July | 1,120 | 1,020 |
| August | 1,140 | 1,040 |
| September | 1,160 | 1,060 |
| October | 1,180 | 1,080 |
| November | 1,200 | 1,100 |
| December | 1,220 | 1,120 |
The Hamps Bio Share Price Target projections highlight consistent growth driven by innovation and market expansion, with long-term potential reaching up to ₹1,220 by 2040.
Hamps Bio Peer Comparison
| Company | Revenue (₹ Cr.) | Profit (₹ Cr.) |
|---|---|---|
| Hamps Bio | 55.78 | 0.36 |
| Cipla | 29,800 | 4,200 |
| Lupin | 19,500 | 1,800 |
Hamps Bio’s diversified product range provides a unique market position compared to its larger competitors.
FAQs
1. What is the Hamps Bio share price target for 2025?
The target ranges between ₹60 and ₹85 by December 2025.
2. How is Hamps Bio positioned in its industry?
The company’s dual focus on pharmaceuticals and FMCG products ensures a diversified revenue stream.
3. What drives Hamps Bio’s growth?
Growth is fueled by advanced manufacturing, e-commerce expansion, and increased brand visibility.
Final Words
The Hamps Bio share price target demonstrates consistent growth potential, driven by strategic market positioning and financial stability. Investors looking for long-term gains can consider this stock as a promising addition to their portfolios.
